Skip to main content
Smart Investors Daily
ST

NASDAQ · STRM

Streamline Health Solutions, Inc.

Healthcare · Medical - Healthcare Information Services

$5.33

Up+$0.00 (+0.00%)

Updated Aug 25, 2026, 12:50 PM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
23.23M
P/E ratio
-2.43
Dividend yield
0.00%
52-week range
— – —
Volume
4.06K
Avg. volume
81.94K

Price performance

STRM price history

1M range · 0 trading sessions · Daily adjusted prices

STRM does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest STRM news

The latest Smart Investors Daily articles mentioning STRM.

STRM research

Overview

Company profile and research snapshot.

Company profile

Streamline Health Solutions, Inc. offers health information technology solutions and associated services for hospitals and health systems in the United States and Canada. It provides computer software-based solutions, professional consulting, and auditing and coding services, which capture, aggregate, and translate structured and unstructured data to deliver predictive insights. The company also offers coding and clinical documentation improvement (CDI) solutions, which include an integrated cloud-based software suite, CDI, and abstracting and physician query; and eValuator, a coding analysis platform, as well as software services. In addition, it provides financial management solutions, including accounts receivable management, denials management, claims processing, spend management, and audit management; patient care solutions; Cerner Command Language (CCL) reporting; and custom integration services for CDI/abstracting, training, and audit services. The company sells its solutions and services through direct sales force and reseller partnerships. Streamline Health Solutions, Inc. was incorporated in 1989 and is based in Alpharetta, Georgia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
STRM recent ratings
DateFirmRatingTarget
May 20, 2022Lake StreetBuy
Open full forecast

News briefing

No generated briefing is available yet.

prnewswire.com · Dec 3, 2025

STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy

CAMBRIDGE, Mass. , Dec. 3, 2025 /PRNewswire/ -- STRM.BIO, a start-up biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced that it has been awarded a contract from the Advanced Research Projects Agency for Health (ARPA-H) through its Engineering of Immune Cells Inside the Body (EMBODY) program.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.